Literature DB >> 25378588

Severe vascular calcification and tumoral calcinosis in a family with hyperphosphatemia: a fibroblast growth factor 23 mutation identified by exome sequencing.

Anuja Shah1, Clinton J Miller2, Cynthia C Nast3, Mark D Adams4, Barbara Truitt2, John A Tayek5, Lili Tong1, Parag Mehtani1, Francisco Monteon6, John R Sedor7, Erica L Clinkenbeard8, Kenneth White8, Rajnish Mehrotra1, Janine LaPage1, Patricia Dickson9, Sharon G Adler1, Sudha K Iyengar2.   

Abstract

BACKGROUND: Tumoral calcinosis is an autosomal recessive disorder characterized by ectopic calcification and hyperphosphatemia.
METHODS: We describe a family with tumoral calcinosis requiring amputations. The predominant metabolic anomaly identified in three affected family members was hyperphosphatemia. Biochemical and phenotypic analysis of 13 kindred members, together with exome analysis of 6 members, was performed.
RESULTS: We identified a novel Q67K mutation in fibroblast growth factor 23 (FGF23), segregating with a null (deletion) allele on the other FGF23 homologue in three affected members. Affected siblings had high circulating plasma C-terminal FGF23 levels, but undetectable intact FGF23 or N-terminal FGF23, leading to loss of FGF23 function.
CONCLUSIONS: This suggests that in human, as in experimental models, severe prolonged hyperphosphatemia may be sufficient to produce bone differentiation proteins in vascular cells, and vascular calcification severe enough to require amputation. Genetic modifiers may contribute to the phenotypic variation within and between families.
© The Author 2014. Published by Oxford University Press on behalf of ERA-EDTA. All rights reserved.

Entities:  

Keywords:  FGF23; hyperphosphatemia; vascular calcification

Mesh:

Substances:

Year:  2014        PMID: 25378588      PMCID: PMC4240183          DOI: 10.1093/ndt/gfu324

Source DB:  PubMed          Journal:  Nephrol Dial Transplant        ISSN: 0931-0509            Impact factor:   5.992


  41 in total

1.  Vascular calcification and osteoporosis--the nature of the nexus.

Authors:  Mishaela R Rubin; Shonni J Silverberg
Journal:  J Clin Endocrinol Metab       Date:  2004-09       Impact factor: 5.958

2.  Elastin degradation and vascular smooth muscle cell phenotype change precede cell loss and arterial medial calcification in a uremic mouse model of chronic kidney disease.

Authors:  Ashwini Pai; Elizabeth M Leaf; Mohga El-Abbadi; Cecilia M Giachelli
Journal:  Am J Pathol       Date:  2011-02       Impact factor: 4.307

3.  Novel conformation-specific antibodies against matrix gamma-carboxyglutamic acid (Gla) protein: undercarboxylated matrix Gla protein as marker for vascular calcification.

Authors:  Leon J Schurgers; Kirsten J F Teunissen; Marjo H J Knapen; Martijn Kwaijtaal; Rob van Diest; Ad Appels; Chris P Reutelingsperger; Jack P M Cleutjens; Cees Vermeer
Journal:  Arterioscler Thromb Vasc Biol       Date:  2005-06-16       Impact factor: 8.311

Review 4.  Vascular calcification: pathobiology of a multifaceted disease.

Authors:  Linda L Demer; Yin Tintut
Journal:  Circulation       Date:  2008-06-03       Impact factor: 29.690

Review 5.  Vascular calcification: pathophysiology and risk factors.

Authors:  Neal X Chen; Sharon M Moe
Journal:  Curr Hypertens Rep       Date:  2012-06       Impact factor: 5.369

6.  A novel recessive mutation in fibroblast growth factor-23 causes familial tumoral calcinosis.

Authors:  Tobias Larsson; Xijie Yu; Siobhan I Davis; Mohamad S Draman; Sean D Mooney; Michael J Cullen; Kenneth E White
Journal:  J Clin Endocrinol Metab       Date:  2005-02-01       Impact factor: 5.958

7.  Phosphate regulation of vascular smooth muscle cell calcification.

Authors:  S Jono; M D McKee; C E Murry; A Shioi; Y Nishizawa; K Mori; H Morii; C M Giachelli
Journal:  Circ Res       Date:  2000-09-29       Impact factor: 17.367

8.  Correlations of serum concentrations of 1,25-dihydroxyvitamin D, phosphorus, and parathyroid hormone in tumoral calcinosis.

Authors:  K W Lyles; D L Halsey; N E Friedman; B Lobaugh
Journal:  J Clin Endocrinol Metab       Date:  1988-07       Impact factor: 5.958

9.  Serum phosphorus levels associate with coronary atherosclerosis in young adults.

Authors:  Robert N Foley; Allan J Collins; Charles A Herzog; Areef Ishani; Philip A Kalra
Journal:  J Am Soc Nephrol       Date:  2008-11-05       Impact factor: 10.121

10.  Increased Wnt5a mRNA Expression in Advanced Atherosclerotic Lesions, and Oxidized LDL Treated Human Monocyte-Derived Macrophages.

Authors:  Pooja M Bhatt; Christopher J Lewis; Denise L House; Chad M Keller; Leonard D Kohn; Mitchell J Silver; Kelly D McCall; Douglas J Goetz; Ramiro Malgor
Journal:  Open Circ Vasc J       Date:  2012
View more
  12 in total

Review 1.  Phosphate Toxicity in CKD: The Killer among Us.

Authors:  Cynthia S Ritter; Eduardo Slatopolsky
Journal:  Clin J Am Soc Nephrol       Date:  2016-02-10       Impact factor: 8.237

2.  Phenotypic and Genotypic Characterization and Treatment of a Cohort With Familial Tumoral Calcinosis/Hyperostosis-Hyperphosphatemia Syndrome.

Authors:  Mary Scott Ramnitz; Pravitt Gourh; Raphaela Goldbach-Mansky; Felasfa Wodajo; Shoji Ichikawa; Michael J Econs; Kenneth E White; Alfredo Molinolo; Marcus Y Chen; Theo Heller; Jaydira Del Rivero; Patricia Seo-Mayer; Bita Arabshahi; Malaka B Jackson; Sarah Hatab; Edward McCarthy; Lori C Guthrie; Beth A Brillante; Rachel I Gafni; Michael T Collins
Journal:  J Bone Miner Res       Date:  2016-09-20       Impact factor: 6.741

Review 3.  Inherited Arterial Calcification Syndromes: Etiologies and Treatment Concepts.

Authors:  Yvonne Nitschke; Frank Rutsch
Journal:  Curr Osteoporos Rep       Date:  2017-08       Impact factor: 5.096

Review 4.  Familial tumoral calcinosis: a valuable vehicle for discovery.

Authors:  Orson W Moe
Journal:  Nephrol Dial Transplant       Date:  2014-08-21       Impact factor: 5.992

Review 5.  Hyperphosphatemic familial tumoral calcinosis secondary to fibroblast growth factor 23 (FGF23) mutation: a report of two affected families and review of the literature.

Authors:  M Chakhtoura; M S Ramnitz; N Khoury; G Nemer; N Shabb; A Abchee; A Berberi; M Hourani; M Collins; S Ichikawa; G El Hajj Fuleihan
Journal:  Osteoporos Int       Date:  2018-06-20       Impact factor: 4.507

6.  Conditional Deletion of Murine Fgf23: Interruption of the Normal Skeletal Responses to Phosphate Challenge and Rescue of Genetic Hypophosphatemia.

Authors:  Erica L Clinkenbeard; Taryn A Cass; Pu Ni; Julia M Hum; Teresita Bellido; Matthew R Allen; Kenneth E White
Journal:  J Bone Miner Res       Date:  2016-03-04       Impact factor: 6.741

Review 7.  Congenital Hyperphosphatemic Conditions Caused by the Deficient Activity of FGF23.

Authors:  Nobuaki Ito; Seiji Fukumoto
Journal:  Calcif Tissue Int       Date:  2020-01-22       Impact factor: 4.333

8.  A 23-year-old patient with secondary tumoral calcinosis: Regression after subtotal parathyroidectomy: A case report.

Authors:  Katharina E Niemann; Feride Kröpil; Martin F Hoffmann; Marlon O Coulibaly; Thomas A Schildhauer
Journal:  Int J Surg Case Rep       Date:  2016-04-11

Review 9.  Hyperphosphatemic Tumoral Calcinosis: Pathogenesis, Clinical Presentation, and Challenges in Management.

Authors:  Alison M Boyce; Alisa E Lee; Kelly L Roszko; Rachel I Gafni
Journal:  Front Endocrinol (Lausanne)       Date:  2020-05-08       Impact factor: 5.555

Review 10.  Tumoral calcinosis in the cervical spine: a case report and review of the literature.

Authors:  Rui Guo; Tatsuya Kurata; Tetsushi Kondo; Takao Imanishi; Tetsutaro Mizuno; Toshihiko Sakakibara; Yuichi Kasai
Journal:  J Med Case Rep       Date:  2017-10-27
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.